0

Is Cost-Effectiveness Analysis Racist?

Performing and using cost-effectiveness analyses is a core activity for many of us working in HEOR. Many shortcomings of CEA are well known (it fails to account for budget impact, “real option value”, “the value of hope”, etc.), but CEA as currently performed has an even bigger problem than any of those: equity. Continue Reading

0

Generating evidence for optimal market access – an Executive Interview with Jeff Anderson and Rosemary Jose, OPEN Health

Jeff Anderson is CEO of the Evidence & Access practice and Rosemary Jose leads Strategic Market Access strategy and activities. They talk about current dynamics in the healthcare industry and the challenges of generating evidence for optimal market access. Continue Reading

0

The things you need to know about the digital transformation of primary research

In the rapidly evolving market access landscape, it’s important to quickly identify current payer perspectives to determine future trends. High-quality, rapid primary research can be key to fast-forwarding your strategy. Continue Reading

0

Using Innovative Data Analytics for Market Access

Dr. Patti Peeples, CEO of HealthEconomics.com, sat down with Walter Bouwmeester, Real-World Evidence and Data Analytics Lead in Europe, to discuss the use of data analytics to support multidimensional health economics and outcomes research (HEOR) in Europe. Continue Reading

0

Changing the Clinical Trial Paradigm for Rare and Orphan (R&O) Diseases using Real-World Evidence

Interview with Flora Sandra Siami, MPH. Vice President of Clinical Research, Regulatory Affairs, and Quality Assurance at HealthCore-NERI. Dr. Patti Peeples, CEO of HealthEconomics.Com, sat down with Flora Sandra Siami, MPH, Vice President of Clinical Research, Regulatory Affairs, and Quality… Continue Reading